Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-l-cysteine

Toxicology and Applied Pharmacology

Volumn 238, Issue 1, 2009, Pages 90-99

  Kim, Sungkyoon ^a   Kim, David ^b   Pollack, Gary M ^c   Collins, Leonard B ^a   Rusyn, Ivan ^a  

^a IL   (United States)

^b SYNGENTA CROP PROTECTION   (United States)

^c Division of Pharmacotherapy   (United States)

Author keywords

Dichloroacetic acid; Metabolism; Pharmacokinetics; S (1,2 dichlorovinyl) l cysteine; S (1,2 dichlorovinyl)glutathione; Trichloroacetic acid; Trichloroethylene

Indexed keywords

(1,2 DICHLOROVINYL)CYSTEINE; (1,2 DICHLOROVINYL)GLUTATHIONE; DICHLOROACETIC ACID; TRICHLOROACETIC ACID; TRICHLOROETHYLENE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GLUTATHIONE METABOLISM; LIVER CARCINOGENESIS; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; RAT; RISK ASSESSMENT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CARCINOGENS; CYSTEINE; DICHLOROACETATE; GLUTATHIONE; HALF-LIFE; MALE; MICE; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; RISK ASSESSMENT; TIME FACTORS; TRICHLOROACETIC ACID; TRICHLOROETHYLENE;

MUS; RATTUS; RODENTIA;

EID: 66049105044     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.04.019     Document Type: Article

References (50)

1. Abbas R., and Fisher J.W. A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. Toxicol. Appl. Pharmacol. 147 (1997) 15-30
2. ATSDR. Toxicological Profile for Trichloroethylene. Agency for Toxic Substances and Disease Registry (1997), U.S. Department of Health and Human Services, Washington, DC
3. Barton H.A., and Clewell III H.J. Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment. Environ. Health Perspect. 108 Suppl. 2 (2000) 323-334
4. Bois F.Y. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ. Health Perspect. 108 Suppl. 2 (2000) 307-316
5. Boroujerd M. Pharmacokinetics: Principles and Applications (2001), McGraw-Hill/Appleton & Lange, New York
6. Brent R.P. Algorithms for Minimization without Derivatives (1972), Prentice-Hall, Englewood Cliffs, N.J
7. Bronley-DeLancey A., McMillan D.C., McMillan J.M., Jollow D.J., Mohr L.C., and Hoel D.G. Application of cryopreserved human hepatocytes in trichloroethylene risk assessment: relative disposition of chloral hydrate to trichloroacetate and trichloroethanol. Environ. Health Perspect. 114 (2006) 1237-1242
8. Bruning T., and Bolt H.M. Renal toxicity and carcinogenicity of trichloroethylene: key results, mechanisms, and controversies. Crit. Rev. Toxicol. 30 (2000) 253-285
9. Bull R.J. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. Environ. Health Perspect. 108 Suppl. 2 (2000) 241-259
10. Bull R.J., Sanchez I.M., Nelson M.A., Larson J.L., and Lansing A.J. Liver tumor induction in B6C3F1 mice by dichloroacetate and trichloroacetate. Toxicology 63 (1990) 341-359
11. Burnham K.P., and Anderson D.R. Model Selection and Multimodel Inference: a Practical Information-theoretic Approach (2002), Springer, New York
12. Cai H., and Guengerich F.P. Mechanism of aqueous decomposition of trichloroethylene oxide. J. Am. Chem. Soc. 121 (1999) 11656-11663
13. Cai H., and Guengerich F.P. Acylation of protein lysines by trichloroethylene oxide. Chem. Res. Toxicol. 13 (2000) 327-335
14. Caldwell J.C., Keshava N., and Evans M.V. Difficulty of mode of action determination for trichloroethylene: an example of complex interactions of metabolites and other chemical exposures. Environ. Mol. Mutagen. 49 (2008) 142-154
15. Chiu W.A., Caldwell J.C., Keshava N., and Scott C.S. Key scientific issues in the health risk assessment of trichloroethylene. Environ. Health Perspect. 114 (2006) 1445-1449
16. Chiu W.A., Okino M.S., Lipscomb J.C., and Evans M.V. Issues in the pharmacokinetics of trichloroethylene and its metabolites. Environ. Health Perspect. 114 (2006) 1450-1456
17. Clewell H.J., Gearhart J.M., Gentry P.R., Covington T.R., VanLandingham C.B., Crump K.S., and Shipp A.M. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal. 19 (1999) 547-558
18. Clewell III H.J., Gentry P.R., Covington T.R., and Gearhart J.M. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ. Health Perspect. 108 Suppl. 2 (2000) 283-305
19. D'Souza R.W., Bruckner J.V., and Feldman S. Oral and intravenous trichloroethylene pharmacokinetics in the rat. J. Toxicol. Environ. Health 15 (1985) 587-601
20. Deangelo A.B., George M.H., and House D.E. Hepatocarcinogenicity in the male B6C3F1 mouse following a lifetime exposure to dichloroacetic acid in the drinking water: dose-response determination and modes of action. J. Toxicol. Environ. Health A 58 (1999) 485-507
21. Evans M.V., and Andersen M.E. Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. Toxicol. Sci. 54 (2000) 71-80
22. Fisher J.W. Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites. Environ. Health Perspect. 108 Suppl. 2 (2000) 265-273
23. Fisher J.W., Gargas M.L., Allen B.C., and Andersen M.E. Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. Toxicol. Appl. Pharmacol. 109 (1991) 183-195
24. Georgita C., Albu F., David V., and Medvedovici A. Nonlinear calibrations on the assay of dilitiazem and two of its metabolites from plasma samples by means of liquid chromatography and ESI/MS(2) detection: application to a bioequivalence study. Biomed. Chromatogr. 22 (2008) 289-297
25. Goeptar A.R., Commandeur J.N., Van Ommen B., van Bladeren P.J., and Vermeulen N.P. Metabolism and kinetics of trichloroethylene in relation to toxicity and carcinogenicity. Relevance of the mercapturic acid pathway. Chem. Res. Toxicol. 8 (1995) 3-21
26. Guengerich F.P. Covalent binding to apoprotein is a major fate of heme in a variety of reactions in which cytochrome P-450 is destroyed. Biochem. Biophys. Res. Commun. 138 (1986) 193-198
27. Herren-Freund S.L., Pereira M.A., Khoury M.D., and Olson G. The carcinogenicity of trichloroethylene and its metabolites, trichloroacetic acid and dichloroacetic acid, in mouse liver. Toxicol. Appl. Pharmacol. 90 (1987) 183-189
28. Ketcha M.M., Stevens D.K., Warren D.A., Bishop C.T., and Brashear W.T. Conversion of trichloroacetic acid to dichloroacetic acid in biological samples. J. Anal. Toxicol. 20 (1996) 236-241
29. Kim S., Vermeulen R., Waidyanatha S., Johnson B.A., Lan Q., Rothman N., Smith M.T., Zhang L., Li G., Shen M., Yin S., and Rappaport S.M. Using urinary biomarkers to elucidate dose-related patterns of human benzene metabolism. Carcinogenesis 27 (2006) 772-781
30. Kishi R., Harabuchi I., Ikeda T., Katakura Y., and Miyake H. Acute effects of trichloroethylene on blood concentrations and performance decrements in rats and their relevance to humans. Br. J. Ind. Med. 50 (1993) 470-480
31. Lash L.H., Putt D.A., Brashear W.T., Abbas R., Parker J.C., and Fisher J.W. Identification of S-(1,2-dichlorovinyl)glutathione in the blood of human volunteers exposed to trichloroethylene. J. Toxicol. Environ. Health, A 56 (1999) 1-21
32. Lash L.H., Fisher J.W., Lipscomb J.C., and Parker J.C. Metabolism of trichloroethylene. Environ. Health Perspect. 108 Suppl. 2 (2000) 177-200
33. Lash L.H., Parker J.C., and Scott C.S. Modes of action of trichloroethylene for kidney tumorigenesis. Environ. Health Perspect. 108 Suppl. 2 (2000) 225-240
34. Lash L.H., Putt D.A., and Parker J.C. Metabolism and tissue distribution of orally administered trichloroethylene in male and female rats: identification of glutathione- and cytochrome P-450-derived metabolites in liver, kidney, blood, and urine. J. Toxicol. Environ. Health, A 69 (2006) 1285-1309
35. Lipscomb J.C., Mahle D.A., Brashear W.T., and Barton H.A. Dichloroacetic acid: metabolism in cytosol. Drug Metab. Dispos. 23 (1995) 1202-1205
36. McKinney L.L., Picken J.C., Weakley F.B., Eldridge A.C., Campbell R.E., Cowan J.C., and Biester H.E. Possible toxic factor of trichloroethylene-extracted soybean oil mea. J. Am. Chem. Soc. 81 (1959) 909-915
37. Merdink J.L., Gonzalez-Leon A., Bull R.J., and Schultz I.R. The extent of dichloroacetate formation from trichloroethylene, chloral hydrate, trichloroacetate, and trichloroethanol in B6C3F1 mice. Toxicol. Sci. 45 (1998) 33-41
38. Merdink J.L., Bull R.J., and Schultz I.R. Trapping and identification of the dichloroacetate radical from the reductive dehalogenation of trichloroacetate by mouse and rat liver microsomes. Free Radic. Biol. Med. 29 (2000) 125-130
39. Merdink J.L., Robison L.M., Stevens D.K., Hu M., Parker J.C., and Bull R.J. Kinetics of chloral hydrate and its metabolites in male human volunteers. Toxicology 245 (2008) 130-140
40. Miller R.E., and Guengerich F.P. Oxidation of trichloroethylene by liver microsomal cytochrome P-450: evidence for chlorine migration in a transition state not involving trichloroethylene oxide. Biochemistry 21 (1982) 1090-1097
41. Moghaddam A.P., Abbas R., Fisher J.W., Stavrou S., and Lipscomb J.C. Formation of dichloroacetic acid by rat and mouse gut microflora, an in vitro study. Biochem Biophys. Res. Commun. 228 (1996) 639-645
42. National Research Council. Assessing the Human Health Risks of Trichloroethylene: Key Scientific Issues (2006), The National Academies Press, Washington, D.C
43. National Toxicology Program. Carcinogenesis studies of trichloroethylene (without epichlorohydrin) (CAS No. 79-01-6) in F344/N rats and B6C3F1 mice (gavage studies). Natl. Toxicol. Prog. Tech. Rep. Ser. 243 (1990) 1-174
44. Pastino G.M., Yap W.Y., and Carroquino M. Human variability and susceptibility to trichloroethylene. Environ. Health Perspect. 108 Suppl. 2 (2000) 201-214
45. Prout M.S., Provan W.M., and Green T. Species differences in response to trichloroethylene. I. Pharmacokinetics in rats and mice. Toxicol. Appl. Pharmacol. 79 (1985) 389-400
46. Rappaport S.M., and Kupper L.L. Quantitative Exposure Assessment (2008), Rappaport, SM, El Cerrito, CA, U.S.A
47. Schultz I.R., Merdink J.L., Gonzalez-Leon A., and Bull R.J. Dichloroacetate toxicokinetics and disruption of tyrosine catabolism in B6C3F1 mice: dose-response relationships and age as a modifying factor. Toxicology 173 (2002) 229-247
48. Srinivas N.R. Applicability of nonlinear calibration regression for quantitative determination of parent and metabolite(s) in bioequivalence assessment. Biomed. Chromatogr. 22 (2008) 1315-1317
49. US AF-EPA, 2004. Development of a physiologically-based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Prepared for U.S. Air Force by U.S. Air Force-U.S. Environmental Protection Agency Trichloroethylene Physiologically-Based Pharmacokinetic Model Workgroup.
50. Withey J.R., Collins B.T., and Collins P.G. Effect of vehicle on the pharmacokinetics and uptake of four halogenated hydrocarbons from the gastrointestinal tract of the rat. J. Appl. Toxicol. 3 (1983) 249-253